Durvalumab Archives - Medical Conferences

Adjuvant durvalumab does not improve survival in completely resected NSCLC

Presented By

Prof. Glenwood Goss, Ottawa Hospital, Canada

Trial

Phase 3, BR.31

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:15

Perioperative durvalumab combined with neoadjuvant chemotherapy improves survival in bladder cancer

Presented By

Prof. Thomas Powles, University of London; Barts Cancer Center, UK

Trial

Phase 3, NIAGARA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:49

Durvalumab plus chemotherapy enhances 3-year survival in advanced biliary tract cancer

Presented By

Prof. Do-Youn Oh, Seoul National University, Korea

Trial

Phase 3, TOPAZ-1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:53

High pCR rate after neoadjuvant Dato-DXd plus durvalumab therapy

Presented By

Dr Jane Meisel, Emory School of Medicine, GA, USA & Dr Rebecca Shatsky, University of California San Diego, CA, USA

Trial

I-SPY2.2

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:38

Consolidation with durvalumab improves survival in LS-SCLC

Presented By

Dr David Spigel, Sarah Cannon Research Institute, TN, USA

Trial

Phase 3, ADRIATIC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:23

MATTERHORN: FLOT plus durvalumab leads to high pCR rate in gastric cancer

Presented By

Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, MATTERHORN

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:19

EMERALD-1: TACE plus immunotherapy meets primary endpoint in unresectable HCC

Presented By

Dr Riccardo Lencioni, University of Pisa, Italy

Trial

Phase 3, EMERALD-1

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:57

Gene expression profiles predict benefit of neoadjuvant immune checkpoint therapy in triple-negative breast cancer

Presented By

Dr Hanna Huebner, Erlangen University Hospital, Germany

Trial

Phase 2, GeparNuevo

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:49

Immune checkpoint inhibition improves PFS in non-BRCA-mutated ovarian cancer

Presented By

Dr Philipp Harter, Kliniken Essen-Mitte, Germany

Trial

Phase 3, DUO-O

Conference

ASCO 2023

Type

Peer-reviewed article

1 August 2023 12:44

Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial

Presented By

Dr Filippo Pietrantonio, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Trial

Phase 2, INFINITY

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:19

POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?

Presented By

Prof. Solange Peters, Lausanne University, Switzerland

Trial

Phase 3, POSEIDON

Conference

WCLC 2022

Type

News article

23 August 2022 10:47

Exploratory treatment options fail in ccRCC

Presented By

Prof. Thomas Powles, University of London, UK

Trial

Phase 2, CALYPSO

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:18

In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy

Presented By

Dr Francesco Cortiula, Maastricht University Medical Center, the Netherlands

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC

Presented By

Dr Lukas Käsmann, University Hospital Munich, Germany

Trial

Phase 3

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

Durvalumab after sequential CRT safe in stage III, unresectable NSCLC

Presented By

Dr Marina Garassino, University of Chicago, IL, USA

Trial

Phase 2, PACIFIC-6

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC

Presented By

Prof. Rina Hui, University of Sydney, Australia

Trial

Phase 3, PACIFIC

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Presented By

Dr Edward Garon, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, POSEIDON

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:36

Characteristics of long-term survivors in the CASPIAN trial

Presented By

Dr Niels Reinmuth, Asklepios Lung Clinic, Germany

Trial

Phase 3, CASPIAN

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:34

Outcomes of real-world CANTABRICO trial match results from CASPIAN

Presented By

Dr Dolores Isla, Hospital Clinico Universitario Lozano Blesa, Spain

Trial

CANTABRICO

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:33

ELCC 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ELCC 2022

19 April 2022 10:43

No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma

Presented By

Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, BAYOU

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:19

TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer

Presented By

Dr Do-Youn Oh, Seoul National University College of Medicine, South Korea

Trial

Phase 3, TOPAZ-1

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:09

HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC

Presented By

Prof. Ghassan Abou-Alfa, Memorial Sloan Kettering Center, NY, USA

Trial

Phase 3, HIMALAYA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:05

ASCO GI 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GI 2022

8 February 2022 12:37

Three-year OS follow-up from CASPIAN trial

Presented By

Dr Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain

Trial

Phase 3, CASPIAN

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:32

Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma

Presented By

Prof. Thomas Powles, Barts Cancer Centre, London, UK

Trial

Phase 3, DANUBE

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:26

Durvalumab after chemoradiation proven safe in elderly NSCLC patients

Presented By

Dr. Adrian Sacher, Princess Margaret Cancer Centre, Toronto, ON, Canada

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 12:21

Doubling overall survival in US veterans with stage 3 non-small cell lung cancer

Presented By

Dr. Nithya Ramnath, University of Michigan

Trial

PACIFIC

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 12:17

5-year PACIFIC data hold strong in NSCLC

Presented By

Dr. Camille Hertzka, AstraZeneca

Trial

Phase 3, PACIFIC

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 12:05

Early-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab With Stereotactic Body Radiotherapy

Presented By

Dr Nassar Altorki, New York Presbyterian-Weill Cornell Medical Center, New York, USA

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 11:29

Novel imaging biomarkers predict benefit in stage 3 NSCLC treated with chemoradiation and durvalumab

Presented By

Dr. Khalid Jazieh, Cleveland Clinic, Ohio, USA

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 11:24

T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Presented By

Dr Fabrice André, Institut Gustave Roussy, Paris, France

Trial

Phase 2, DESTINY-Breast07

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 10:55

4-year PACIFIC data hold strong in NSCLC

Presented By

Dr. Camille Hertzka , AstraZeneca

Trial

Phase 3, PACIFIC

Journal

Physician's Weekly

Conference

ESMO Virtual Congress 2020

13 April 2021 18:31

ES-SCLC: CASPIAN trial perspectives from Prof. Jonathan Goldman

Presented By

Prof. Jonathan Goldman, Prof. Luis Paz-Ares

Trial

Phase 3, CASPIAN

Journal

Physician Weekly

Conference

ASCO Annual Meeting 2020

13 April 2021 16:27

Better prediction of favourable responses to immune checkpoint inhibitors in mUC

Presented By

Dr Marie Alt, Princess Margaret Cancer Centre, Canada

Conference

ASCO GU 2021

24 March 2021 15:02

Preoperative immunotherapy in early stage NSCLC safe and feasible

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:07

First-line immune-combination therapies in mUC

Trial

Phase 3, KEYNOTE-361

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:43

ES-SCLC: tremelimumab + durvalumab + chemotherapy misses endpoint

Presented By

Prof. Luis G. Paz-Ares, Hospital 12 de Octubre, Spain

Trial

Phase 3, CASPIAN

Conference

ASCO 2020

8 September 2020 13:50

Durvalumab added to etoposide improves outcomes in ES-SCLC

Trial

CASPIAN

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 23:06

High need for biomarkers for stage III lung cancer

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 18:03

Post-discontinuation immunotherapy in PACIFIC

Presented By

Dr Phillip Dennis, Dr Marina Garassino

Trial

Phase 3, PACIFIC

Conference

ELCC 2019

Type

Peer-reviewed article

25 June 2019 23:23

I-O monotherapy

Presented By

Prof. Martin Reck, Airway Research Center North, Grosshansdorf, Germany

Trial

CheckMate 026, Keynote-024, Checkmate 227, MYSTIC, B-F1RST

Conference

ELCC 2019

Type

Peer-reviewed article

25 June 2019 23:13

Post-study immunotherapy in MYSTIC

Presented By

Dr Niels Reinmuth, Asklepios Lung Clinic, Munich-Gauting, Germany

Trial

Phase 3, MYSTIC

Conference

ELCC 2019

Type

Peer-reviewed article

25 June 2019 13:26

Immunotherapy in SCLC: trial data

Presented By

Dr Enriqueta Felip, Vall d’Hebron University Hospital, Spain

Trial

CA184-156, CheckMate-451, CASPIAN, Keynote-604, Checkmate 032

Conference

ELCC 2019

Type

Peer-reviewed article

25 June 2019 08:15

Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer

Presented By

Dr Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, USA

Trial

Phase 3, PACIFIC

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 23:28